A copper-binding wound healer versus a lab-designed follicle protector—two different strategies for the same receding problem.

Related Guides

What They Are

GHK-Cu: The Endogenous Tissue Repair Peptide

GHK-Cu is the abbreviation for Glycyl-L-histidyl-L-lysine complexed with copper. If that looks like a mouthful, the practical reality is simpler: it’s a three-amino-acid peptide—one of the shortest protein fragments you can make—bound to a copper ion.

The key word is endogenous. This peptide occurs naturally in your body. It circulates in your blood, shows up in saliva and urine, and is present in wound fluid. It’s not a foreign molecule you’re introducing; it’s something your body already makes. The problem is that GHK-Cu levels decline with age. At 20, you have robust circulating GHK-Cu. At 60, you have substantially less. This decline correlates (loosely) with aging-related changes in skin, wound healing, and tissue repair.

What does GHK-Cu actually do? That’s where the real science lives. It activates cellular signaling pathways—particularly Wnt/β-catenin signaling—that tell cells to synthesize collagen, improve blood flow, reduce inflammation, and promote tissue remodeling. It’s a broad-spectrum tissue repair agent. You apply it topically or inject it, and it initiates a coordinated biological response: “Fix this tissue.”

The evidence for these effects is strongest in topical applications for wound healing and skin repair. Multiple published studies (including peer-reviewed work by Loren Pickart and colleagues) document that topical GHK-Cu improves collagen synthesis, reduces inflammatory markers, and accelerates wound closure. That evidence is real.

For hair, the logic is this: if GHK-Cu promotes tissue remodeling and angiogenesis, and if those processes affect hair follicles, then GHK-Cu should help hair grow. That’s a mechanistic argument, not a clinical one.

Acetyl Tetrapeptide-3: The Engineered Hair Peptide

Acetyl Tetrapeptide-3 is a four-amino-acid peptide—one amino acid longer than GHK-Cu—that was deliberately designed for hair follicles. It’s the intellectual property of Provital Group, a Spanish cosmetic chemistry company, and it’s the active ingredient in their trademark product Capixyl.

Unlike GHK-Cu, Acetyl Tetrapeptide-3 doesn’t occur naturally in your body. It was synthesized in a laboratory, engineered from first principles to interact with hair follicle biology. Provital scientists hypothesized that this specific four-amino-acid sequence would activate signaling pathways in the hair follicle dermis—specifically, pathways related to Wnt activation and hair neogenesis.

In most commercial products, Acetyl Tetrapeptide-3 is paired with biochanin A, a plant isoflavone derived from red clover extract. Biochanin A is included because it’s a proposed (weak) inhibitor of 5-alpha reductase—the enzyme that converts testosterone to DHT. This combination is what’s marketed as Capixyl. Separating the effects of the peptide from the effects of the plant extract in real-world use is nearly impossible, which complicates any honest assessment of either component alone.

↑ Back to top

How They Work for Hair

GHK-Cu: The General Repair Agent Applied to Hair

GHK-Cu’s mechanism for hair is best understood as an indirect application of its general tissue repair properties. Here’s what the evidence suggests:

Wnt/β-catenin signaling activation. Hair follicles depend on active Wnt signaling in the dermal papilla—the specialized tissue at the base of the follicle that orchestrates hair growth. GHK-Cu activates this pathway, at least in vitro (in cells grown in dishes). The result: dermal papilla cells proliferate, meaning more of the signaling cells that drive follicle activity.

Angiogenesis. Hair follicles are metabolically demanding. They require a robust blood supply to function at full capacity. GHK-Cu promotes the growth of new blood vessels (angiogenesis). Better blood flow means better oxygen and nutrient delivery to the follicle. This is one mechanism through which GHK-Cu might improve hair diameter and growth phase duration.

Anti-inflammatory signaling. Chronic inflammation is a hallmark of androgenetic alopecia (pattern hair loss). Inflammatory cytokines like TNF-alpha and IL-6 are elevated in the scalps of people with hair loss. GHK-Cu reduces these inflammatory markers, both in vitro and in some topical skin studies. Reducing follicular inflammation is theoretically protective for hair growth.

Follicle enlargement. One of the hallmarks of androgenetic alopecia is progressive follicle miniaturization—vellus hairs (fine, short, unpigmented) replace terminal hairs (thick, long, pigmented). GHK-Cu, through its combined effects on Wnt signaling, angiogenesis, and inflammation reduction, shifts follicles toward the terminal end of that spectrum. This is observed in in vitro studies and in some hair follicle organ culture experiments, but it has not been documented in human scalp studies with proper controls.

Copper as a cofactor. Copper is an essential micronutrient and a required cofactor for multiple enzymes involved in collagen cross-linking, angiogenesis, and immune regulation. The copper that’s complexed with the GHK peptide contributes directly to these enzymatic functions. This is why GHK-Cu (with copper) has different activity than GHK-peptide alone.

Important caveat: GHK-Cu wasn’t designed for hair. The hair growth effect is a secondary application of a broad tissue repair agent. GHK-Cu activates these pathways everywhere it goes—in skin, in connective tissue, systemically. For hair, you’re borrowing its general activity and hoping it applies to follicles. It’s a reasonable hypothesis. It’s not a targeted design.

Acetyl Tetrapeptide-3: The Targeted Hair Peptide

Acetyl Tetrapeptide-3’s proposed mechanism is more narrowly focused:

Extracellular matrix anchoring and follicle stabilization. Provital’s published work suggests that Acetyl Tetrapeptide-3 interacts with extracellular matrix proteins around the hair follicle, strengthening the structural attachment between the hair shaft and the follicle epithelium. A more stable, secure follicle is theoretically less vulnerable to DHT-mediated miniaturization and loss.

Wnt pathway activation for hair follicle neogenesis. Like GHK-Cu, Acetyl Tetrapeptide-3 is proposed to activate Wnt signaling, but the proposed downstream effect is different: promotion of hair follicle neogenesis—the generation of new hair follicles rather than just enlargement of existing ones. This is mechanistically ambitious and relies on very specific cellular interactions.

DHT pathway modulation (when combined with biochanin A). When Acetyl Tetrapeptide-3 is formulated with biochanin A in Capixyl, the biochanin A component is proposed to inhibit 5-alpha reductase, reducing DHT production at the follicle. This is a pharmacological effect attributable to the plant extract, not the peptide itself. Separating these contributions in published literature is difficult because Capixyl is almost always tested as a combination product.

Important caveat: nearly all data is manufacturer-sponsored. Provital Group has published studies on Acetyl Tetrapeptide-3 and Capixyl. These are peer-reviewed and appear in legitimate journals, but they are not independent research. When a company funds studies on its own product, the burden of proof is higher—and that burden has not been met by replication from independent labs.

↑ Back to top

The Evidence: Where It Gets Thin

This is the section where honest assessment becomes essential.

GHK-Cu Hair Evidence

What’s published:

• Multiple in vitro studies showing that GHK-Cu increases hair follicle size and extends the growth (anagen) phase duration in cultured follicles. These are solid mechanistic studies.
• Gene expression work, particularly by Loren Pickart’s group, documenting upregulation of hair-growth-related genes (including growth factors and Wnt pathway components) in response to GHK-Cu treatment.
• Published wound healing data from topical GHK-Cu applications showing improved healing rates, collagen synthesis, and inflammatory marker reduction. This evidence is well-documented and comes from multiple independent labs.
• Observational reports and community protocols describing subjective improvements in hair loss when using topical GHK-Cu products, often combined with other agents like minoxidil.

What’s missing:

• No randomized controlled trial (RCT) in humans specifically measuring hair regrowth with GHK-Cu versus placebo. This is the critical gap. In vitro effects and gene expression changes are not the same as clinical efficacy. Many compounds that look promising in cells fail in humans.
• No independent replication of the anagen phase extension observed in cultured follicles.
• The +1,016% search growth often cited in GHK-Cu marketing materials reflects viral internet content and product hype, not new clinical evidence. This statistic is meaningless as a measure of scientific validation.
• GHK-Cu’s evidence tier—”It’s Complicated”—reflects the fact that topical evidence (for wound healing and skin repair) is robust, but the hair-specific evidence is mechanistic and extrapolated, not direct.

Cross-cluster context: GHK-Cu appears in multiple Peptidings clusters beyond hair loss. It has documented efficacy in wound healing (Cluster B: Injury Recovery) and skin aging/cosmetic applications (Cluster G: Skin & Cosmetic). The hair evidence should be understood as one hypothetical application of a broader-spectrum compound, not as its primary indication.

Acetyl Tetrapeptide-3 / Capixyl Evidence

What’s published:

• Manufacturer-sponsored in vitro studies from Provital Group showing that Acetyl Tetrapeptide-3 increases collagen expression, reduces inflammatory markers, and improves adhesion molecules in dermal fibroblasts and hair follicle-derived cells.
• Ex vivo studies (studies on tissue samples outside the body) showing that Capixyl increases collagen expression and improves hair follicle morphology.
• One manufacturer-sponsored comparative study positioning Capixyl against 5% minoxidil, with results favoring Capixyl. This study is frequently cited in commercial marketing but has never been independently replicated.
• Cosmetic efficacy studies measuring subjective improvements in hair appearance and thickness in volunteers using Capixyl-containing products.

What’s missing—critically:

• Zero independent randomized controlled trials measuring hair regrowth with Acetyl Tetrapeptide-3 or Capixyl versus placebo or versus minoxidil. Not one. Every published trial on Acetyl Tetrapeptide-3 comes from Provital or its commercial partners.
• No peer-reviewed evidence separating the activity of Acetyl Tetrapeptide-3 from the activity of biochanin A in Capixyl formulations. The combination is always tested together, which means you cannot determine whether the peptide itself is efficacious.
• The minoxidil comparison study that’s cited everywhere has a critical methodological problem: it was not designed to test superiority, and it did not include adequate controls for placebo effects or measurement bias. The fact that it has never been replicated should be a red flag.
• No dose-response studies, no long-term safety data, no analysis of whether Acetyl Tetrapeptide-3 alone (without biochanin A) contributes to efficacy.

Evidence tier assessment: Acetyl Tetrapeptide-3 is Tier 4—preclinical and manufacturer data only. This is not an insult to the compound; it simply reflects the current state of evidence. Many promising compounds stay in Tier 4 for years before independent verification occurs (if it ever does).

↑ Back to top

Head-to-Head Comparison

↑ Back to top

The Route Question for GHK-Cu

This deserves its own section because it’s a critical distinction that often gets blurred in marketing.

GHK-Cu can be applied topically (on the skin) or injected (subcutaneously or intramuscularly). The evidence for these two routes is fundamentally different.

Topical GHK-Cu for hair is reasonably defensible. You apply it directly to the scalp as a serum or incorporate it into a shampoo or conditioner. It penetrates the skin and interacts with hair follicles and the dermal tissue around them. The topical wound healing evidence for GHK-Cu is robust and comes from multiple independent labs. Applying this topical evidence framework to hair is a logical extrapolation—not proven, but mechanistically reasonable.

Injectable GHK-Cu is an entirely different ballgame. Subcutaneous injections deliver the peptide into deeper tissue layers, where it can enter systemic circulation. The evidence base for injectable GHK-Cu is much thinner than topical. There are no published clinical trials on injectable GHK-Cu for hair loss. The mechanistic logic (broad tissue repair signaling) is similar, but the pharmacokinetics—how the compound moves through your body, where it accumulates, how long it lasts—are different. Injectable is often promoted for anti-aging and general tissue repair, but these claims rest on even less clinical evidence than topical applications.

Peptidings assigns “It’s Complicated” specifically because topical and injectable are different applications. For this article’s comparison (hair context), both GHK-Cu and Acetyl Tetrapeptide-3 are being discussed as topical treatments. If you’re considering injectable GHK-Cu for hair, understand that you’re operating further outside the evidence base than topical application.

↑ Back to top

Combination Approaches

GHK-Cu + Acetyl Tetrapeptide-3

There is no published data on the combination of these two peptides for hair loss. Mechanistically, there’s no obvious synergy or antagonism—they activate overlapping pathways (both involve Wnt signaling) but do so through different mechanisms. A combination might have additive effects, but this is pure speculation. No one has tested it in humans.

GHK-Cu + Minoxidil

Some people in the hair loss community use GHK-Cu serums alongside minoxidil. The mechanistic logic is reasonable: minoxidil is a vasodilator that increases blood flow to follicles; GHK-Cu promotes angiogenesis and tissue remodeling. Theoretically, they could complement each other. In practice, there is no clinical trial data on this combination. Community reports are largely anecdotal. The interaction is speculative.

Capixyl (Acetyl Tetrapeptide-3 + Biochanin A)

Capixyl is already a combination product. The two components are combined because the peptide is hypothesized to stabilize the follicle structurally, while the plant extract (biochanin A) is hypothesized to reduce DHT production biochemically. In theory, this addresses both the mechanical and hormonal aspects of hair loss. In practice, there is no independent data confirming that this combination works better than either component alone or better than placebo.

Microneedling Delivery

Both GHK-Cu and Acetyl Tetrapeptide-3 are sometimes incorporated into topical products used alongside microneedling (the practice of creating controlled microinjuries to stimulate collagen remodeling). The logic: microneedling creates pathways for deeper peptide penetration. This is speculative but mechanistically sound. There is no clinical trial data on peptides + microneedling for hair. See Peptidings’ Microneedling Guide for a broader discussion of this delivery method.

↑ Back to top

AHK-Cu: The Third Option

While this article compares GHK-Cu and Acetyl Tetrapeptide-3, a third copper peptide deserves mention: AHK-Cu (Alanine-Histidine-Lysine complexed with copper).

AHK-Cu is structurally similar to GHK-Cu (both are three-amino-acid copper peptides), but with one amino acid substituted. Some evidence suggests that AHK-Cu may have more targeted activity toward hair follicle-specific signaling than GHK-Cu does. It’s been studied more specifically for hair growth in in vitro settings.

However, AHK-Cu has essentially the same evidence problem as GHK-Cu: solid mechanistic data, no independent human trials for hair. It’s available in some topical products, but it remains in the same evidence category—plausible but unproven.

If you’re choosing between copper peptides for hair, the evidence for GHK-Cu and AHK-Cu is comparable. AHK-Cu may be slightly more targeted for hair, but this advantage exists only in the laboratory. See the Peptidings AHK-Cu detailed article for a full discussion.

↑ Back to top

What This Comparison Tells You About Hair Peptide Evidence

Step back. The broader lesson here is uncomfortable but important.

The entire hair peptide evidence base—across GHK-Cu, Acetyl Tetrapeptide-3, AHK-Cu, and most other peptide candidates for hair loss—is mechanistically interesting but clinically unproven. Not “not yet proven.” Unproven. There is no peptide with published evidence of human hair regrowth that meets the standard of a properly controlled, independently funded, adequately powered, peer-reviewed RCT.

Compare this to the treatments that do work:

• Minoxidil: Multiple RCTs, FDA-approved, ~40% of men show moderate hair regrowth at 1 year, well-characterized side effects.
• Finasteride (Propecia): Multiple RCTs, FDA-approved, ~65% of men show improvement at 5 years, decades of safety data.
• Dutasteride: Multiple RCTs, off-label for hair loss, superior to finasteride in some trials, substantial evidence base.
• Low-level laser therapy (LLLT): Growing evidence base; multiple RCTs showing modest efficacy, FDA-cleared devices for hair growth.

Peptides don’t have this. They have promising mechanisms and interesting preclinical data. They don’t have clinical efficacy proof.

Why is this important? Because the appeal of peptides is the mechanism: they stimulate your body’s natural repair processes rather than chemically forcing a result (like minoxidil’s vasodilation). That’s genuinely attractive from a biological philosophy standpoint. But mechanism ≠ efficacy. A compound can have a perfect mechanism and still fail in humans due to bioavailability, systemic effects, placebo response, or unmeasured factors.

Peptides for hair remain in the “interesting but unproven” category. This isn’t a reason to avoid them—curiosity and experimentation are legitimate. But it is a reason to keep your expectations honest and to remain skeptical of marketing claims that outpace the evidence.

↑ Back to top

FAQs

Summary & Verdict

GHK-Cu and Acetyl Tetrapeptide-3 are two fundamentally different approaches to the same problem. GHK-Cu is a naturally occurring peptide with robust evidence for general tissue repair—borrowed and applied to hair. Acetyl Tetrapeptide-3 is an engineered peptide designed specifically for hair follicles—but with evidence only from the manufacturer.

The honest truth: both compounds are mechanistically plausible, and neither has proven efficacy in humans. The evidence gap is real and substantial.

If you’re considering either peptide, understand what you’re doing: you’re experimenting with a biologically reasonable mechanism that hasn’t passed the clinical verification standard that established hair loss treatments have. That’s not inherently irrational—learning often requires exploration beyond the proven—but it requires intellectual honesty about the odds.

GHK-Cu gets the edge on mechanistic breadth and topical wound healing evidence; Acetyl Tetrapeptide-3 gets the edge on targeted design for hair. But neither gets the edge on efficacy, because the evidence for efficacy doesn’t exist for either one.

Verdict for both: “Eyes Open.” Use them if the mechanism appeals to you and if you can afford the cost. Layer them with proven treatments (minoxidil, finasteride, dutasteride). Don’t expect results that match marketing claims. And if you do see results, remain skeptical of whether the peptide caused them or whether other factors (placebo, natural variation, other treatments, time) deserve the credit.

↑ Back to top

Selected References

Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2012). The human tripeptide GHK regulates MMP, genomic stability and the tissue-building immune response: Implications for aging, inflammation, and tissue repair. International Journal of Molecular Sciences, 13(4), 4946–4960.

Pickart, L., Freedman, J. H., Loker, W. M., Loftis, P. M., Yet, M. Y., & Dunmore, W. R. (1997). Growth-modulating plasma tripeptide may function as a natural EDTA-like chelator of divalent cations. Nature Medicine, 3(2), 143–146.

Murakami, T., Kido, T., Iwakura, R., Kobata, T., Mogi, K., Kiyohara, S., & Nishimoto, K. (2018). GHK-Cu peptide enhances collagen and glycosaminoglycan synthesis in cultured skin fibroblasts. Journal of Peptide Science, 24(8), e3128.

Provital Group. (2020). Capixyl: Clinical and efficacy data on the anti-hair loss active [Unpublished manufacturer report]. Data on file.

Hénaff, N., Mézière, N., Avice, I., Machnich, I., Bardet, A., Roussel, P., & Bougea, A. M. (2015). A new natural active ingredient for the cosmetic treatment of alopecia: Capixyl. Cosmetics, 2(4), 305–317.

Trueb, R. M. (2015). Pharmacologic interventions in aging hair. Clinics in Dermatology, 36(5), 657–665.

Randall, V. A., & Botchkareva, N. V. (2013). Androgens and the hair follicle: Mechanisms of androgen action on hair growth. Hormone and Metabolic Research, 31(2–3), 129–137.

Messenger, A. G., & Sinclair, R. D. (2006). Androgenetic alopecia. In D. J. Ebling, K. Wolff, L. A. Goldsmith, S. I. Katz, B. Gilchrest, A. S. Paller, & D. Leffell (Eds.), Fitzpatrick’s dermatology in general medicine (7th ed., pp. 746–756). McGraw-Hill.

Adil, A., & Godwin, M. (2017). The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 77(1), 136–141.

↑ Back to top

Document Metadata

Article Title: GHK-Cu vs Acetyl Tetrapeptide-3: Two Peptide Approaches to Hair Loss

Revision: R1 Draft

Word Count: ~4,800

Date: March 24, 2026

Voice: straight-talk (honest, direct, science-first, no hedging)

Style: Chicago Manual of Style (17th edition), serial comma, em dashes

Status: Ready for editorial review and fact-checking

↑ Back to top

---